Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lixte Biotechnology Holdings Inc LIXT

Healthcare Biotechnology
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint... see more

Recent & Breaking News (NDAQ:LIXT)

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Accesswire September 11, 2024

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

GlobeNewswire September 4, 2024

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

GlobeNewswire August 26, 2024

LIXTE Biotechnology Provides Update On Recent Activities and Developments

GlobeNewswire August 19, 2024

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

GlobeNewswire August 15, 2024

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Accesswire August 14, 2024

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

GlobeNewswire June 14, 2024

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

GlobeNewswire June 14, 2024

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

GlobeNewswire June 6, 2024

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

GlobeNewswire June 3, 2024

LIXTE Biotechnology Holdings Provides Update on Recent Activities

GlobeNewswire May 20, 2024

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on "Therapeutic Over-Activation in Cancer"

GlobeNewswire May 8, 2024

NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES

GlobeNewswire March 27, 2024

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

GlobeNewswire March 21, 2024

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

GlobeNewswire February 27, 2024

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

GlobeNewswire February 26, 2024

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

GlobeNewswire January 29, 2024

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

GlobeNewswire November 13, 2023

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

GlobeNewswire October 16, 2023

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

GlobeNewswire October 9, 2023